These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11227671)

  • 21. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
    Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.
    Akuta N; Tsubota A; Suzuki F; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2003 Jan; 38(1):91-7. PubMed ID: 12480565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.
    Pas SD; de Man RA; Fries E; Osterhaus AD; Niesters HG
    J Clin Virol; 2002 Jul; 25(1):63-71. PubMed ID: 12126723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
    Akuta N; Suzuki F; Kobayashi M; Matsuda M; Sato J; Takagi K; Tsubota A; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2003 Dec; 71(4):504-10. PubMed ID: 14556262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    Intervirology; 2003; 46(3):182-9. PubMed ID: 12867757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
    Pariente A; Tachet A; Poveda JD
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
    [No Abstract]   [Full Text] [Related]  

  • 27. No benefit to continue lamivudine therapy after emergence of YMDD mutations.
    Liaw YF; Chien RN; Yeh CT
    Antivir Ther; 2004 Apr; 9(2):257-62. PubMed ID: 15134188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.
    Lin CL; Tsai SL; Lee TH; Chien RN; Liao SK; Liaw YF
    Gut; 2005 Jan; 54(1):152-61. PubMed ID: 15591521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S333-7. PubMed ID: 12472959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [YMDD motif and its significance].
    Goto T; Kato N; Omata M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():46-50. PubMed ID: 15453283
    [No Abstract]   [Full Text] [Related]  

  • 31. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.
    Orlando R; Tosone G; Portella G; Veropalumbo E; D'Onofrio M; Piazza M
    Infection; 2008 Oct; 36(5):472-4. PubMed ID: 17962902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
    Yang DH; Xie YJ; Liang WF; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
    Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
    J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
    Ramezani A; Velayati AA; Roshan MR; Gachkar L; Banifazl M; Keyvani H; Aghakhani A
    Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea.
    Paik YH; Chung HY; Ryu WS; Lee KS; Lee JS; Kim JH; Lee CK; Chon CY; Moon YM; Han KH
    J Hepatol; 2001 Jul; 35(1):92-8. PubMed ID: 11495048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.
    França PH; Coelho HS; Brandão CE; Segadas JA; Quintaes RF; Carrilho FJ; Ono-Nita S; Mattos AA; Tovo C; Gouvea VS; Sablon E; Vanderborght BO
    Braz J Med Biol Res; 2007 Dec; 40(12):1605-14. PubMed ID: 17713642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
    Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
    J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.